| Filed On | Filing |
|---|---|
| 13 May 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this Second Amended and Restated 2017 Equity Incentive Plan (the “Plan”) of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Compa... |
| 26 Jan 2022 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
X4 Pharmaceuticals, Inc. (the “Company”) intends to share with investors the amount of cash, cash equivalents and restricted cash it had on hand as of December 31, 2021, as well as the principal amount of outstanding debt, its number of ... |
| 18 Oct 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As reported in the Original Filing, on September 18, 2019, the Board of Directors (the “Board”) of the Company appointed William E. Aliski to the Board as a Class II director. Committee assignments for Mr. Aliski were not determined as o... |
| 17 May 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 May 2019 |
8-K/A: Financial Statements and Exhibits
This License Agreement (this “Agreement”) is executed as of July 10, 2014 (the “Effective Date”) by and between Genzyme Corp., a corporation having an address at 500 Kendall Street, Cambridge, MA 02142 (“Genzyme” or “Licensor”) and X4 Ph... |
| 03 Apr 2019 |
8-K/A: Financial Statements and Exhibits
To the Board of Directors and Stockholders of X4 Therapeutics, Inc. (formerly known as X4 Pharmaceuticals, Inc.) |
Loading...